Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition (ICI) versus cisplatin-based chemotherapy (CBC) in muscle-invasive bladder cancer (MIBC).

被引：0
|
作者：
Khaki, Ali Raza [1 ]
Shan, Yong [2 ]
Nelson, Richard [3 ]
Kaul, Sapna [2 ]
Gore, John L. [1 ]
Grivas, Petros [1 ]
Williams, Stephen B. [2 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Univ Texas Med Branch, Galveston, TX 77555 USA
[3] Univ Utah, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.419
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
419
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Role of neoadjuvant chemotherapy in muscle-invasive bladder cancer: Clinical and cost effectiveness
    Goonewardene, Sanchia S.
    Bahl, Amit
    Persad, Raj
    JOURNAL OF CLINICAL UROLOGY, 2015, 8 (04) : 279 - 284
  • [22] Muscle invasive bladder cancer (MIBC) demonstrates neoadjuvant cisplatin-based chemotherapy (NAC) related changes in molecular subtype and immune infiltration.
    Funt, Samuel Aaron
    Solovyov, Alexander
    Faltas, Bishoy Morris
    Iyer, Gopa
    Boyd, Mariel Elena
    Cipolla, Catharine Kline
    Regazzi, Ashley Marie
    Teo, Min Yuen
    Lee, Chung-Han
    Al-Ahmadie, Hikmat
    Rosenberg, Jonathan E.
    Greenbaum, Benjamin
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [23] Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer
    Plimack, Elizabeth R.
    Dunbrack, Roland L.
    Brennan, Timothy A.
    Andrake, Mark D.
    Zhou, Yan
    Serebriiskii, Ilya G.
    Slifker, Michael
    Alpaugh, Katherine
    Dulaimi, Essel
    Palma, Norma
    Hoffman-Censits, Jean
    Bilusic, Marijo
    Wong, Yu-Ning
    Kutikov, Alexander
    Viterbo, Rosalia
    Greenberg, Richard E.
    Chen, David Y. T.
    Lallas, Costas D.
    Trabulsi, Edouard J.
    Yelensky, Roman
    McConkey, David J.
    Miller, Vincent A.
    Golemis, Erica A.
    Ross, Eric A.
    EUROPEAN UROLOGY, 2015, 68 (06) : 959 - 967
  • [24] IDENTIFICATION OF MOLECULAR BIOMARKERS OF CISPLATIN-BASED CHEMOSENSITIVITY IN PATIENTS UNDERGOING NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER
    Shah, Paras
    Kozel, Zachary
    Lee, Annette
    Korsunsky, Ilya
    Shih, Andrew
    Yaskiv, Oksana
    Vira, Manish
    Bradley, Thomas
    Zhu, Xinhua
    JOURNAL OF UROLOGY, 2017, 197 (04): : E1196 - E1197
  • [25] Neoadjuvant cisplatin-based chemotherapy in "primary" and "secondary" muscle-invasive bladder cancer-is it a surrogate for molecular subtypes?
    Szarvas, Tibor
    Olah, Csilla
    Reis, Henning
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S176 - S179
  • [26] Defining molecular and laboratory predictive biomarkers of response to cisplatin-based neoadjuvant chemotherapy (NC) in muscle-invasive bladder cancer (MIBC) - preliminary results and future plans
    Leibowitz-Amit, Raya
    Seah, Jo-An
    Berger, Raanan
    Sridhar, Srikala S.
    CANCER RESEARCH, 2014, 74 (19)
  • [27] Contemporary Use of Perioperative Cisplatin-Based Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
    Raj, Ganesh V.
    Karavadia, Saumil
    Schlomer, Bruce
    Arriaga, Yull
    Lotan, Yair
    Sagalowsky, Arthur
    Frenkel, Eugene
    CANCER, 2011, 117 (02) : 276 - 282
  • [28] Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer
    Clark, Peter E.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 821 - 830
  • [29] Cisplatin Neoadjuvant Chemotherapy in an Aging Population With Muscle-Invasive Bladder Cancer
    Gong, Jun
    ONCOLOGY-NEW YORK, 2022, 36 (01): : 30 - 31
  • [30] Identification of molecular biomarkers of cisplatin-based chemosensitivity in patients undergoing neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Shah, Paras Hemant
    Lee, Annette
    Zhu, Xinhua
    Bradley, Thomas Paul
    Vira, Manish Arvind
    Korsunsky, Ilya
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345